XIENCE PRIME is available in a wide size matrix, including XIENCE PRIME SV for little vessels and XIENCE PRIME LL for lengthy lesions. XIENCE Primary reflects Abbott’s commitment to innovation, and based on the positive doctor feedback we’ve received from our post-market evaluations, XIENCE PRIME is poised to become the market-leading drug eluting stent across Europe, said Robert Hance, senior vice president, vascular, Abbott. Building Upon the SPIRIT Body of Evidence In the SPIRIT category of trials, XIENCE V demonstrated superiority to Boston Scientific’s TAXUS Paclitaxel Eluting Coronary Stent System in its primary endpoints in two distinct randomized clinical trials.The company raised an additional $2.during July and August of 2010 65 million through the issuance of equity and warrants.
Alcohol related liver problems on the rise among the young By Dr Ananya Mandal, MD Based on the NHS figures there’s been a huge upsurge in the number of adults treated in medical center for serious liver problems due to drinking too much. The biggest increase in medical center admissions for alcohol-related liver disease has been observed in 25 to 29-year-olds. In 2002-03 a total of 182 males and 100 ladies in England had been treated for it, but by 2009-10 those figures had increased to 291 and 188, up by 60 percent and 88 percent respectively.